Overview

A Study of OV101 in Individuals With Angelman Syndrome (AS)

Status:
Completed
Trial end date:
2020-11-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric subjects with Angelman syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Ovid Therapeutics Inc.
Treatments:
Gaboxadol